



MHRA Strategy to 2030: What it means for patients and the public

Protecting patients is at the heart of our work. Our 2030 Strategy sets out how we will create a regulatory system that works with patients, not just for them. We will continue to protect patient safety while supporting timely access to safe and effective medicines and medical devices. As innovative medicines, AI-enabled medical devices and advanced therapies are developed, we will maintain high standards for safety and effectiveness while adapting how we assess and monitor them.

Patients will see clearer information, a stronger voice in regulatory decisions, faster access to innovation where evidence supports it, and better protection through next-generation safety surveillance. We will continue to work with patients, healthcare professionals and partners across the wider health system to help ensure innovative medicines and technologies reach the patients who need them. We want patients and the public to be involved throughout the regulatory journey, so that lived experience, knowledge and different perspectives help shape our decisions and ensure we understand what matters most to the people who use them.

What will change for patients and the public?

Our priority	What it means for patients and the public
Clearer regulatory information and decisions	By 2027 , we will publish a benefit-risk framework, developed with patients and clinicians, explaining how we assess evidence and make regulatory decisions. This will help make the evidence behind our decisions clearer and support patients and healthcare professionals to make informed choices about treatment.
Information that is easier to access	By 2030 , we aim to make all product information available as structured digital content. This will make information about indications, benefits, risks and emerging safety evidence easier to access and use, while retaining alternative formats for those who need them.
A stronger patient voice	We will strengthen how patients contribute to regulatory decisions, using different ways of involving the public, including deliberative sessions and citizens' assemblies for complex issues.
Easier ways to report concerns	From 2027 , we will begin introducing a more conversational Yellow Card reporting service, making it simpler to report suspected problems with medicines and medical devices. We will also explore integration with the NHS App and other health-system technology.
Stronger safety monitoring throughout a product's life	We will strengthen how we monitor the safety of medicines and medical devices once they are in use. By making better use of health data, scientific expertise and new technologies, we aim to identify emerging safety signals earlier, understand risks more precisely and act quickly when concerns arise.
Stronger action against illegal and unsafe products	We will substantially increase our criminal enforcement capacity to tackle counterfeit, falsified and unauthorised medicines and medical devices, working with partners and online platforms to prevent harmful products reaching the public.
Safe innovation reaching patients sooner	We will work more closely with partners across the health system so that promising medicines and medical technologies can move more smoothly from development into patient care. This includes closer alignment between MHRA licensing and NICE assessment.

